1. Home
  2. ZLAB vs TNET Comparison

ZLAB vs TNET Comparison

Compare ZLAB & TNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • TNET
  • Stock Information
  • Founded
  • ZLAB 2013
  • TNET 1988
  • Country
  • ZLAB China
  • TNET United States
  • Employees
  • ZLAB N/A
  • TNET N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • TNET Business Services
  • Sector
  • ZLAB Health Care
  • TNET Consumer Discretionary
  • Exchange
  • ZLAB Nasdaq
  • TNET Nasdaq
  • Market Cap
  • ZLAB 3.6B
  • TNET 3.9B
  • IPO Year
  • ZLAB 2017
  • TNET 2014
  • Fundamental
  • Price
  • ZLAB $32.54
  • TNET $68.66
  • Analyst Decision
  • ZLAB Buy
  • TNET Hold
  • Analyst Count
  • ZLAB 5
  • TNET 3
  • Target Price
  • ZLAB $54.28
  • TNET $90.00
  • AVG Volume (30 Days)
  • ZLAB 781.8K
  • TNET 429.2K
  • Earning Date
  • ZLAB 08-05-2025
  • TNET 07-25-2025
  • Dividend Yield
  • ZLAB N/A
  • TNET 1.62%
  • EPS Growth
  • ZLAB N/A
  • TNET N/A
  • EPS
  • ZLAB N/A
  • TNET 3.32
  • Revenue
  • ZLAB $418,326,000.00
  • TNET $4,999,000,000.00
  • Revenue This Year
  • ZLAB $44.07
  • TNET $1.90
  • Revenue Next Year
  • ZLAB $49.13
  • TNET $4.13
  • P/E Ratio
  • ZLAB N/A
  • TNET $20.48
  • Revenue Growth
  • ZLAB 43.72
  • TNET 1.19
  • 52 Week Low
  • ZLAB $16.01
  • TNET $65.43
  • 52 Week High
  • ZLAB $44.34
  • TNET $116.26
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 40.19
  • TNET 27.95
  • Support Level
  • ZLAB $34.26
  • TNET $71.47
  • Resistance Level
  • ZLAB $35.72
  • TNET $76.09
  • Average True Range (ATR)
  • ZLAB 1.12
  • TNET 2.08
  • MACD
  • ZLAB -0.54
  • TNET -0.29
  • Stochastic Oscillator
  • ZLAB 3.83
  • TNET 8.38

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About TNET TriNet Group Inc.

TriNet offers outsourced payroll and human capital management solutions for small and midsize businesses via a professional employer organization model. Under the PEO model, TriNet enters a co-employment arrangement and acts as the employer of record for administrative and regulatory purposes for clients' employees, known as worksite employees. Clients leverage the scale and expertise of TriNet to access competitive employee benefits, share employment risk liability, access compliance support, and outsource mission-critical day-to-day HR functions such as payroll and tax administration. Following the acquisition of Zenefits and Clarus R+D in 2022, TriNet derives the minority of its revenue from self-service HCM software and R&D tax credit services.

Share on Social Networks: